← The Wire
RGNXNasdaq
REGENXBIO Inc.
Biological Products, (No Diagnostic Substances) · CIK 1590877
Develops gene therapy treatments using its NAV Technology Platform for genetic defects and therapeutic protein production
⚡ Elevated coverage
$344M
Market cap
$11.83
Last close
+12.9%
1D
+30.4%
5D
2.5M
Volume
Price · last 39 sessions+26.0%
May 4L $5.65 · H $11.83Jun 29
215
Total filings
Jun 29, 2026
Last filing
12/31
Fiscal year end
10-Q10-QMay 14, 202610-Q10-QNov 6, 202510-Q10-QAug 7, 202510-Q10-QMay 12, 202510-Q10-QNov 6, 202410-Q10-QAug 1, 202410-Q10-QMay 8, 202410-Q10-QNov 8, 202310-Q10-QAug 2, 202310-Q10-QMay 3, 202310-Q10-QNov 3, 202210-Q10-QAug 3, 202210-Q10-QMay 4, 202210-Q10-QNov 2, 202110-Q10-QAug 9, 202110-Q10-QMay 5, 202110-Q10-QNov 4, 202010-Q10-QAug 6, 202010-Q10-QMay 7, 202010-Q10-QNov 5, 201910-Q10-QAug 7, 201910-Q10-QMay 7, 201910-Q10-QNov 7, 201810-Q10-QAug 8, 201810-Q10-QMay 8, 201810-Q10-QNov 8, 201710-Q10-QAug 8, 201710-Q10-QMay 9, 201710-Q10-QNov 9, 201610-Q10-QAug 9, 201610-Q10-QMay 5, 201610-QFORM 10-QNov 5, 2015
Insider Activity
In the 90 days to Mar 10, 2026: 1 sold $53K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 10, 2026 | Pakola SteveChief Medical Officer | Sell | 5,124 | $10.35 | $53K |
| Oct 9, 2025 | Simpson CurranChief Executive Officer | Sell | 20,811 | $12.62 | $263K |
| Sep 29, 2025 | Simpson CurranChief Executive Officer | Sell | 7,624 | $10.03 | $76K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 1 reputable article · skews ▲ positive.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance